glp-1 pathophysiology The Cardiovascular Biology of Glucagon-like Peptide-1: Cell Metabolism Glucagon-like peptide-1 (GLP-1) receptor agonists

Somfai T, Kaneda M, Akagi S, Watanabe S, Haraguchi S, Mizutani E, Dang-Nguyen TQ, Geshi M, Kikuchi K, Nagai T

A drug with high managed care penetration and tight formulary management will see faster branded substitution than one with a significant cash-pay or Medicare Part D patient base, where formulary levers are weaker

Atul Malhotra, MD, a sleep medicine specialist at UC San Diego Health, and co-authors conducted two phase 3, double-blind, randomized controlled trials for tirzepatide in moderate-to-severe OSA patients with obesity who were and were not using CPAP

Nosaka N, Tsujino S, Honda K, Suemitsu H, Kato K (2020) Enhancement of fat oxidation during submaximal exercise in sedentary persons: variations by medium-chain fatty acid composition and age group

Error-related hyperactivity of the anterior cingulate cortex in obsessive-compulsive disorder

W., Santelli, J